Ovation支架系统在不良解剖学特征腹主动脉瘤腔内修复术中的中期结果
该单中心回顾性观察研究纳入2012至2017年接受Ovation Prime或iX支架腔内修复肾下腹主动脉瘤的52例患者,评估其中期疗效与安全性。所有患者均符合Ovation说明书适应证,但仅12%符合Cook和Medtronic装置的说明书标准。结果显示技术成功率100%,30天死亡率为0%,随访期间无动脉瘤相关死亡,无I型或III型内漏,19%出现II型内漏。
要点
- Ovation支架在不良解剖学特征腹主动脉瘤中技术成功率达100%,30天死亡率为0%。
- 中位随访24个月无动脉瘤相关死亡,无I型或III型内漏。
- 19%发生II型内漏,仅1例需再干预;无髂支闭塞,1例因支架扭结需重新内衬。
核心结论
- Ovation支架系统中期 experience 显示对肾下腹主动脉瘤(包括不良解剖学特征者)的治疗安全、持久。
- 许多患者虽不符合其他常用装置的说明书标准,但仍可成功应用Ovation支架。
研究设计与样本
- 单中心回顾性观察研究,纳入2012至2017年接受择期肾下腹主动脉瘤修复的52例患者,使用Ovation Prime或iX支架,至少随访3个月。
- 术后监测包括3个月和1年CT扫描,此后每年 duplex 超声。
- 所有患者均符合Ovation说明书适应证,并评估动脉瘤是否具有对其他常用支架平台而言不良的解剖学特征。
主要发现
- 52例患者中79%为男性,平均年龄75.7岁,平均动脉瘤直径62.5 mm(范围55-107 mm)。
- 技术释放成功率100%,30天死亡率为0%,随访期间(中位24个月,范围3-48个月)无动脉瘤相关死亡。
- 无I型或III型内漏,19%出现II型内漏,其中1例需再干预。
- 无髂支闭塞,1例因支架扭结需重新内衬。
- 所有52例均符合Ovation说明书标准,但仅12%符合Cook和Medtronic装置的说明书标准。
临床怎么用
- 对于解剖学特征不适合其他常用支架平台的肾下腹主动脉瘤患者,Ovation支架可作为治疗选择。
- 术后需监测II型内漏,尽管多数无需干预。
局限性
- 回顾性单中心设计,样本量较小(52例),随访时间有限(中位24个月)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim was the evaluation of mid-term efficacy and safety outcome measures for the Ovation (Endologix, Santa Rosa, CA, USA) stent graft system in the management of infrarenal abdominal aortic aneurysms (iAAA) with adverse anatomy. METHODS: A retrospective observational study of all patients undergoing elective iAAA repair was carried out from 2012 to 2017 using Ovation Prime or iX stent grafts with a minimum of 3 months follow-up at a single UK vascular centre. Post-operative surveillance involved computed tomography scans at 3 months and 1 year, with duplex ultrasound yearly thereafter. Outcome measures were established with retrospective analysis of pre- and post-operative imaging, and included peri-operative mortality, major adverse events, limb complications, aneurysm diameter change, and endoleak rates. All patients were within Ovation instructions for use (IFU), and assessment was made to determine whether aneurysms had anatomical features considered adverse for other commonly used stent graft platforms. RESULTS: Ovation stent grafts were implanted in 52 patients (79% male, mean age 75.7 years) with a mean aneurysm diameter of 62.5 mm (range 55-107 mm). There was 100% technical deployment success. The 30 day mortality was 0% and there was no aneurysm related mortality during follow-up (median 24 months, range 3-48 months). There were no type I or III endoleaks, but 19% developed type II endoleaks with one patient requiring re-intervention. No iliac limb occlusions were identified but one case required relining for limb kinking. All 52 cases were within the IFU for Ovation but only 12% met the IFU criteria for the Cook and Medtronic devices. CONCLUSIONS: The mid-term experience with Ovation demonstrates safe, durable treatment of iAAAs, including those with unfavourable anatomy, frequently off IFU for other commonly used devices.
引用
- Greaves NS, Moore A, Seriki D, et al. Outcomes of Endovascular Aneurysm Repair using the Ovation Stent Graft System in Adverse Anatomy. Eur J Vasc Endovasc Surg. 2017. PMID: 29292208. doi:10.1016/j.ejvs.2017.11.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。